Please try another search
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases primarily in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trail and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. The company was incorporated in 2017 and is headquartered in Beijing, China.
Name | Age | Since | Title |
---|---|---|---|
Robert Taylor Nelsen | 61 | 2018 | Non-Executive Director |
Martin J. Murphy | - | - | Independent Non-executive Director |
Yiu Wa Tsui | 73 | - | Independent Non-executive Director |
Zhi Hong | 59 | 2018 | Co-founder, Executive Chairman of the Board & CEO |
Taiyin Yang | 69 | 2022 | Independent Non-Executive Director |
Gregg Huber Alton | 57 | - | Independent Non-executive Director |
Hui Tang | 63 | - | Independent Non-executive Director |
Ankang Li | 45 | 2021 | Chief Financial & Strategy Officer, Company Secretary and Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review